Dossier assessment

Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-140
Last updated

Report documents

  1. Extract of dossier assessment

    Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 349 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-140_en
  2. Dossier assessment

    Polatuzumab vedotin (relapsed or refractory DLBCL) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 661 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-140

Dossier assessment

Indication:

Adults with relapsed or refractory diffuse large B-cell lymphoma

Result of dossier assessment:
  • after failure of one line of systemic therapy, for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
  • after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy is an option and for whom haematopoietic stem cell transplantation is not an option: added benefit not proven
  • after failure of ≥ 2 lines of systemic therapy, for whom CAR-T cell therapy and haematopoietic stem cell transplantation are not an option: added benefit not proven

Project details

Project no.
A23-140
Commission
Commission awarded on 21.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-140_en

Connected Projects

  1. Dossier assessment

    Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G20-01
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Polatuzumab vedotin (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G22-22
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Polatuzumab vedotin (DLBCL) – Benefit assessment according to § 35a Social Code Book V

    Project no.
    A23-141
    Last updated

    Status: Commission completed

  4. Addendum

    Polatuzumab vedotin (relapsed or refractory DLBCL) – Addendum to Project A23-140

    Project no.
    G24-09
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form